PTH-140 Soluble Plantain Fibre Inhibits The Epithelial Adhesion Of Diarrhoeal Pathogens Clostridium Difficile, Salmonella And Enterotoxigenic E. Coli (etec) Through Interaction With The Intestinal Epithelium. (9th June 2014)

• Record Type: Journal Article
• Authors: Simpson, H; Keita, Å. V.; Söderholm, JD; Rhodes, JM; Campbell, BJ
• Is Part Of: Gut. Volume 63(2014)Supplement 1
• Page Start: A273
• Page End: A274
• Publication Date: 2014-06-09
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-307263.586
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Pathogen-related diarrhoea causes significant morbidity and mortality worldwide. Our studies have previously shown that soluble dietary fibre (non-starch polysaccharides, NSP), particularly from plantain bananas, can inhibit epithelial adherence of diarrhoeal pathogens in vitro and ex vivo ( J. Nutr. Biochem. 2013;24:97–103). Methods: Here we aimed to establish whether plantain NSP exerts its inhibitory effect on pathogen adhesion to intestinal epithelium through either interaction with bacterial carbohydrate-binding proteins (adhesins) or via action on the epithelium itself. Prior to infection (MOI 100) of Caco2 human intestinal epithelial cells with C.difficile (2 h), Salmonella Typhimurium LT2 (1.5 h) or ETEC (1.5 h), monolayers were either 1) pre-treated with plantain NSP (0–10 mg/mL – a concentration that is readily achievable in vivo with dietary supplementation) for 30 min followed by inoculation, 2) pre-treated for 30 min, plantain NSP removed by thorough sterile saline washes before infection, or 3) infected with bacteria that had been pre-treated with NSP for 30 min followed by washing to remove non-adherent soluble fibre. Following infection, non-adherent bacteria were removed by sterile washes and adherent bacteria enumerated by overnight culture colony counts. Results: Plantain NSP (5 mg/mL) significantly decreased bacterial adhesion to Caco2 (% inhibition of adhesion for LT2 89 ± 5%; C.difficile 92.9 ± 2%; ETEC 65.8 ± 1%; all P < 0.001) compared to untreated cells. When plantain NSP was added to epithelial monolayers followed by washing to remove non-adherent fibre prior to infection, bacterial adherence was still markedly reduced (LT2 59.2 ± 5% inhibition; C.difficile 59.2 ± 5%; ETEC 45.0 ± 2%, all P < 0.01). Pre-incubation of bacteria with plantain NSP followed by removal with sterile washes prior to infection resulted in no significant inhibition of adhesion compared to untreated controls. Thus inhibition of bacterial adherence to the epithelium by soluble NSP is mediated via an interaction between the NSP and the epithelium. This is supported by data from Ussing chamber experiments (PLoSOne;In press) showing that pre-treatment of human ileal tissue with plantain NSP results in a marked increase in transmucosal short circuit current (Isc ) implying Cl - secretion (peak ΔIsc 5.86 ± 1.89 µA.cm -2 50 min post-NSP addition; P < 0.01) without any effect on TEER. Conclusion: Soluble plantain NSP exerts its inhibitory effect on C.difficile, ETEC and Salmonella adhesion to the intestinal epithelium via action on the epithelium rather than through interaction with bacterial adhesins. This effect is probably mediated by increased epithelial Cl - secretion. Disclosure of Interest: H. Simpson Grant/research support from: Provexis plc, Bo and Vera Axe:son Johnson Foundation for Nature Medicine Limited and Arcis Biotechnology, Å. Keita: None Declared, J. Söderholm: None Declared, J. Rhodes Consultant for: advisory boards of Atlantic, Procter and Gamble and Falk, Speaker bureau with: Has received speaking honoraria from Abbott, Falk, Ferring, Glaxo Smith Kline, Proctor and Gamble, Schering Plough, Conflict with: Holds a patent with the University of Liverpool and Provexis plc for use of a soluble fibre preparation as maintenance therapy for Crohn's disease, B. Campbell Grant/research support from: Provexis plc, Bo and Vera Axe:son Johnson Foundation for Nature Medicine Limited and Arcis Biotechnology, Speaker bureau with: Received a speaking honorarium from Amgen Inc.